<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466674</url>
  </required_header>
  <id_info>
    <org_study_id>2005.385</org_study_id>
    <nct_id>NCT00466674</nct_id>
  </id_info>
  <brief_title>Treatment of Myeloma in Patients &lt;= 65 Years Old With Response &gt;= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning</brief_title>
  <acronym>IFM 2005-03</acronym>
  <official_title>Treatment of Myeloma in Patients &lt;= 65 Years Old With Response &gt;= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning (IFM 2005-03)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Donor mobilization :

      Donor will be mobilized with G-CSF (Granocyte) sub-cutaneous 10 µg/kg/day during 5 to 6 days.

      Hematopoïetic Stem Cell Harvest:

      By 1, 2, or 3 aphaeresis, a number of 4 x 106 cellules CD34+ /kg is required. If the CD34+ &gt;=
      2 and &lt;= 4x106/kg: the center must decide on the strategy Decision. In case of insufficient
      graft : a Bone Marrow Harvest is recommended Conditioning : Fludarabine - Busulfan - ATG

        -  D-5 : Fludarabine (30 mg/m²)

        -  D-4 : Fludarabine (30 mg/m²)+ Busilvex (0,8 mg/kg every 6 h)

        -  D-3 : Fludarabine (30 mg/m²)+ Busilvex (0,8 mg/kg every 6 h)

        -  D-2 : Fludarabine (30 mg/m²) + ATG (Genzyme) (2.5 mg/Kg)

        -  D-1 : Fludarabine (30 mg/m²) + ATG (Genzyme) (2.5 mg/Kg) GVHD Prophylaxis: CsA alone at
           3 mg/ kg + Methotrexate D1, D3 and D6 only in case of minor ABO incompatibility and with
           an anti A/B antibodies titer&gt; 1/32.

      Transplant : HSC at D0

      • 3 months after Transplantation :

      Disease Evaluation :

        -  If CR : Supervision. Then if progression: 4 cycles of Bortezomib.

        -  If no CR : Bortezomib (4 cycles)

           • Evaluation after Bortezomib cycles

        -  If CR : Supervision. Then, if progression and no GvHD : DLI If no RC and no GVHD : DLI
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of 15% of Event-free survival (EFS) at 3 years after allo HSCT (decrease of the number of deaths and progressions).</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Haematological recovery</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Engraftment rate and graft failure rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The tolerance of Bortezomib after AlloHCST</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CR (Complete Response) length rate defined by Bladé criteria.</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute and chronic GVHD</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of GVHD under treatment by Bortezomib</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chimerism study by competitive PRC</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological study of the graft (ancillary study)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of immunological recovery by the recipient</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRM = Transplant- Related Mortality at 3 months</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TRM = Transplant- Related Mortality at 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of quality of life</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global survival at 3 years and 5 years</measure>
    <time_frame>3 and 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Myeloma</condition>
  <arm_group>
    <arm_group_label>Allogenic Transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reduced intensity conditioning</intervention_name>
    <description>reduced intensity conditioning for allogenic transplant</description>
    <arm_group_label>Allogenic Transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Major patients not under guardianship

          -  Myeloma with high b2 microglobulin level (&gt; 3 mg/l) and/or chromosome 13 deletion,
             and/or translocation t(4;14) stage I DS with high evolutive potential or stage II, III
             DS.

        AND

          -  With response &gt;= 50% and &lt;= 90% after the first AutoHSCT (IFM 2005 01). The evaluation
             must be performed within 2 months after the first AutoHSCT.

          -  with an HLA identical related or unrelated donor ( match 10/10).

          -  Donor and recipient must have signed a written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mauricette Michallet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mohamad Sobh</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2007</study_first_submitted>
  <study_first_submitted_qc>April 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>January 14, 2014</last_update_submitted>
  <last_update_submitted_qc>January 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myeloma</keyword>
  <keyword>RICT</keyword>
  <keyword>conditioning</keyword>
  <keyword>allograft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

